CBT has the required infrastructure, expertise, and experience to perform detailed analytical and functional characterization of biosimilars. We have already published exhaustive comparability exercises of Neupogen, Rituximab and Herceptin biosimilars that exist in Indian markets. We have recently patented FTIR based fingerprinting to eliminate counterfeiting of biotherapeutics.